Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (965) 965
Paper (734) 734
Publication (581) 581
Report (124) 124
Data Set (8) 8
Newspaper Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (858) 858
particle physics (732) 732
high energy physics - experiment (693) 693
physics (693) 693
physics - high energy physics - experiment (660) 660
high energy physics (574) 574
phenomenology (366) 366
cern lhc coll (353) 353
experimental results (333) 333
physics of elementary particles and fields (274) 274
nuclear experiment (250) 250
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (234) 234
physical sciences (223) 223
fysik (222) 222
hep (210) 210
natural sciences (195) 195
naturvetenskap (195) 195
p p: scattering (193) 193
particle physics - experiment (181) 181
p p: colliding beams (179) 179
13000 gev-cms (165) 165
ex (158) 158
scattering [p p] (156) 156
hadron-hadron scattering (146) 146
subatomär fysik (138) 138
subatomic physics (137) 137
colliding beams [p p] (127) 127
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (123) 123
8000 gev-cms (115) 115
atlas (110) 110
astrophysics (106) 106
physics, particles & fields (102) 102
high energy astrophysical phenomena (96) 96
background (82) 82
elementary particles, quantum field theory (77) 77
quantum field theories, string theory (77) 77
science & technology (74) 74
ciências físicas [ciências naturais] (70) 70
collisions (58) 58
detectors (58) 58
mass dependence (58) 58
large hadron collider (53) 53
astronomy, astrophysics and cosmology (49) 49
transverse momentum dependence (49) 49
data analysis method (46) 46
物理学 (46) 46
nuclear and high energy physics (44) 44
measurement science and instrumentation (43) 43
nuclear energy (43) 43
parton distributions (43) 43
rapidity dependence (42) 42
supersymmetry (42) 42
bottom: particle identification (41) 41
instrumentation and detectors (41) 41
nuclear physics, heavy ions, hadrons (40) 40
physics and astronomy (38) 38
classical and quantum gravitation, relativity theory (37) 37
quantum physics (37) 37
cern lab (36) 36
jet: bottom (36) 36
kinematics (36) 36
settore fis/01 - fisica sperimentale (36) 36
z0: leptonic decay (36) 36
astronomy & astrophysics (35) 35
engineering (35) 35
física (34) 34
channel cross section: branching ratio: upper limit (33) 33
differential cross section: measured (33) 33
final state:jet lepton (33) 33
humans (33) 33
settore fis/04 - fisica nucleare e subnucleare (33) 33
hep-ex (32) 32
transverse momentum: missing-energy (32) 32
channel cross section: upper limit (31) 31
decay (29) 29
electroweak interaction (29) 29
leptonic decay [z0] (29) 29
mass spectrum: (29) 29
missing-energy [transverse momentum] (29) 29
sensitivity (29) 29
top: pair production (29) 29
lhc (28) 28
measured [differential cross section] (28) 28
numerical calculations: monte carlo (27) 27
standard model (27) 27
higgs particle: hadroproduction (25) 25
model (25) 25
transverse momentum (25) 25
channel cross section: measured (24) 24
index medicus (24) 24
phase space (24) 24
final state:jet dilepton (23) 23
hadron colliders (23) 23
luminosity (23) 23
medicine, general & internal (23) 23
physik (23) 23
searching (23) 23
structure (22) 22
higgs particle: hadronic decay (21) 21
monte carlo [numerical calculations] (21) 21
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Oral Rivaroxaban for Symptomatic Venous Thromboembolism
by Bauersachs, Rupert and Berkowitz, Scott D and Brenner, Benjamin and Buller, Harry R and Decousus, Herve and Gallus, Alex S and Lensing, Anthonie W and Misselwitz, Frank and Prins, Martin H and Raskob, Gary E and Segers, Annelise and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Bounameaux, Henri and Cohen, Alexander and Davidson, Bruce L and Piovella, Franco and Schellong, Sebastian and The EINSTEIN Investigators and EINSTEIN Investigators and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | THERAPY | DISEASE | PREVENTION | DEEP-VEIN THROMBOSIS | IDRAPARINUX | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Kamphuisen, P and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
In the treatment of patients with acute pulmonary embolism, the efficacy of rivaroxaban, a factor Xa inhibitor, was similar to that of traditional... 
XA INHIBITOR RIVAROXABAN | MEDICINE, GENERAL & INTERNAL | DEEP-VEIN THROMBOSIS | VENOUS THROMBOEMBOLISM | WARFARIN | MOLECULAR-WEIGHT HEPARIN | Recurrence | Thiophenes - therapeutic use | Follow-Up Studies | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Rivaroxaban | Vitamin K - antagonists & inhibitors | Female | Drug Therapy, Combination | Morpholines - adverse effects | Morpholines - therapeutic use | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | International Normalized Ratio | Pulmonary Embolism - mortality | Pulmonary Embolism - drug therapy | Aged | Hemorrhage - chemically induced | Pulmonary embolism | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Anticoagulants | Embolisms | Pulmonary arteries | Thrombosis | Bone surgery | Patients | Bleeding | Embolism | Hepatitis | Blood pressure | Thromboembolism | Health risk assessment | Veins & arteries | Vitamin K | Enoxaparin | Morpholines | Hemorrhage | Life Sciences | Human health and pathology | Thiophenes | Pulmonary Embolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
by Buller, Harry R and Cohen, Ander T and Davidson, Bruce and Decousus, Herve and Gallus, Alex S and Gent, Michael and Pillion, Gerard and Piovella, Franco and Prins, Martin H and Raskob, Gary E and The van Gogh Investigators and van Gogh Investigators
The New England Journal of Medicine, ISSN 0028-4793, 09/2007, Volume 357, Issue 11, pp. 1094 - 1104
The long-acting factor X inhibitor idraparinux was compared with a standard antithrombotic regimen in two randomized trials, one for the treatment of deep... 
HEPARIN | MEDICINE, GENERAL & INTERNAL | THROMBOSIS | Recurrence | Follow-Up Studies | Venous Thrombosis - drug therapy | Humans | Middle Aged | Oligosaccharides - therapeutic use | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Heparin - therapeutic use | Male | Oligosaccharides - adverse effects | Treatment Outcome | Anticoagulants - adverse effects | Heparin - adverse effects | Incidence | Pulmonary Embolism - mortality | Vitamin K - antagonists & inhibitors | Female | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Thrombophlebitis | Anticoagulants (Medicine) | Drug therapy | Health aspects | Comparative studies | Clinical trials | Medical research | Inhibitor drugs | Blood clots | Anticoagulants | Venous Thrombosis | Pharmacology | Oligosaccharides | Hemorrhage | Life Sciences | Pulmonary Embolism | Heparin | Pharmaceutical sciences | Vitamin K
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text An update of consensus guidelines for warfarin reversal
by Tran, Huyen A and Chunilal, Sanjeev D and Harper, Paul L and Tran, Huy and Wood, Erica M and Gallus, Alex S and Australasian Society of Thrombosis and Haemostasis (ASTH)
Medical Journal of Australia, ISSN 0025-729X, 03/2013, Volume 198, Issue 4, pp. 198 - 199
For most warfarin indications, the target international normalised ratio (INR) is 2.0–3.0 (venous thromboembolism and single mechanical heart valve excluding... 
Hematologic diseases | MEDICINE, GENERAL & INTERNAL | Antifibrinolytic Agents - therapeutic use | Plasma | Anticoagulants - administration & dosage | Drug Administration Schedule | Administration, Oral | Surgical Procedures, Operative | Humans | Hemorrhage - prevention & control | International Normalized Ratio - standards | Warfarin - administration & dosage | Drug Monitoring - standards | Dose-Response Relationship, Drug | Postoperative Care | Vitamin K 1 - therapeutic use | Blood Coagulation Factors - therapeutic use | Hemorrhage - chemically induced | Drugs | Care and treatment | Practice guidelines (Medicine) | Anticoagulants (Medicine) | Product/Service Evaluations | Health aspects | Thrombosis | Blood clot
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
by Baker, Ross I and Coughlin, Paul B and Salem, Hatem H and Gallus, Alex S and Harper, Paul L and Wood, Erica M and Warfarin Reversal Consensus Grp and Warfarin Reversal Consensus Group
Medical Journal of Australia, ISSN 0025-729X, 11/2004, Volume 181, Issue 9, pp. 492 - 497
For most warfarin indications, the target maintenance international normalised ratio (INR) is 2–3. Risk factors for bleeding complications with warfarin use... 
Hematologic diseases | Pharmaceutical preparations | 10-MG | MEDICINE, GENERAL & INTERNAL | THERAPY | VENOUS THROMBOEMBOLISM | ANTICOAGULANT TREATMENT | HEMORRHAGIC COMPLICATIONS | VITAMIN-K | INTENSITY | RANDOMIZED-TRIAL | ATRIAL-FIBRILLATION | BLEEDING COMPLICATIONS | Plasma | Anticoagulants - administration & dosage | Thromboembolism - chemically induced | Humans | Warfarin - adverse effects | Hemorrhage - prevention & control | Drug Monitoring - methods | Warfarin - administration & dosage | Patient Selection | Thromboembolism - prevention & control | Vitamin K 1 - therapeutic use | Perioperative Care - standards | Adult | Drug Administration Schedule | Administration, Oral | Risk Factors | International Normalized Ratio - methods | International Normalized Ratio - standards | Anticoagulants - adverse effects | Evidence-Based Medicine | Drug Monitoring - standards | Warfarin - pharmacokinetics | Hemorrhage - drug therapy | Blood Coagulation Factors - therapeutic use | Patient Education as Topic - standards | Perioperative Care - methods | Anticoagulants - pharmacokinetics | Hemorrhage - chemically induced | Care and treatment | Warfarin | Research | Thrombosis | Blood clot
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
by Büller, Harry R, Prof and Gallus, Alex S, Prof and Pillion, Gerard, MD and Prins, Martin H, Prof and Raskob, Gary E, Prof and Cassiopea Investigators
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9811, pp. 123 - 129
Summary Background Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DEEP-VEIN THROMBOSIS | ANTITHROMBOTIC THERAPY | Acute Disease | Anticoagulants - administration & dosage | Double-Blind Method | Humans | Middle Aged | Male | Warfarin - administration & dosage | Enoxaparin - administration & dosage | Adolescent | Intention to Treat Analysis | Aged, 80 and over | Factor X - antagonists & inhibitors | Adult | Female | Pulmonary Embolism - drug therapy | Aged | Drug Therapy, Combination | Biotin - administration & dosage | Biotin - analogs & derivatives | Oligosaccharides - administration & dosage | Pulmonary embolism | Heparin | Research | Drug therapy | Health aspects | Complications and side effects | Warfarin | Enoxaparin | Dosage and administration | Studies | Anticoagulants | Medical imaging | Drug dosages | Biotin | Oligosaccharides | Life Sciences | Human health and pathology | Factor X | Pulmonary Embolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy
by Raskob, Gary E and Gallus, Alex S and Sanders, Paul and Thompson, John R and Agnelli, Giancarlo and Buller, Harry R and Cohen, Alexander T and Ramacciotti, Eduardo and Weitz, Jeffrey I
Thrombosis and Haemostasis, ISSN 0340-6245, 2016, Volume 115, Issue 4, pp. 809 - 816
Summary Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE). We therefore examined... 
Stroke, Systemic or Venous Thromboembolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Extended Prophylaxis of Venous Thromboembolism with Idraparinux
by Buller, Harry R and Cohen, Ander T and Davidson, Bruce and Decousus, Herve and Gallus, Alex S and Gent, Michael and Pillion, Gerard and Piovella, Franco and Prins, Martin H and Raskob, Gary E and The van Gogh Investigators and van Gogh Investigators
The New England Journal of Medicine, ISSN 0028-4793, 09/2007, Volume 357, Issue 11, pp. 1105 - 1112
The high risk of recurrent venous thromboembolism in patients with idiopathic venous thrombosis or pulmonary embolism is reason for extended thromboprophylaxis... 
LONG-TERM | MEDICINE, GENERAL & INTERNAL | FONDAPARINUX | THROMBOSIS | WARFARIN | EPISODE | PULMONARY-EMBOLISM | DISEASE | INITIAL TREATMENT | ORAL ANTICOAGULANT-THERAPY | SECONDARY PREVENTION | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Male | Secondary Prevention | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Oligosaccharides - administration & dosage | Double-Blind Method | Drug Administration Schedule | Venous Thrombosis - drug therapy | Oligosaccharides - therapeutic use | Kaplan-Meier Estimate | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Oligosaccharides - adverse effects | Treatment Outcome | Anticoagulants - adverse effects | Pulmonary Embolism - mortality | Pulmonary Embolism - drug therapy | Aged | Hemorrhage - chemically induced | Thrombophlebitis | Hemorrhage | Health aspects | Risk factors | Vitamin K | Studies | Anticoagulants | Pulmonary arteries | Blood pressure | Drug therapy | Drug dosages | Blood clots | Recurrence | Venous Thrombosis | Factor Xa | Pharmacology | Oligosaccharides | Life Sciences | Pulmonary Embolism | Kaplan-Meiers Estimate | Pharmaceutical sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
by Buller, Harry R and Gallus, Alex S and Pillion, Gerard and Prins, Martin H and Raskob, Gary E
Lancet, ISSN 0140-6736, 01/2012, Volume 379, Issue 9811, pp. 123 - 129
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial
by Raskob, Gary E and Gallus, Alex S and Sanders, Paul and Thompson, John R and Agnelli, Giancarlo and Buller, Harry R and Cohen, Alexander T and Ramacciotti, Eduardo and Weitz, Jeffrey I
Thrombosis and haemostasis, ISSN 0340-6245, 2016, Volume 115, Issue 4, pp. 809 - 816
Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE). We therefore examined the early... 
Pulmonary embolism | Venous thrombosis | Anticoagulant therapy | FONDAPARINUX | SAFETY | DEEP-VEIN THROMBOSIS | INITIAL TREATMENT | RISK | HEPARIN | DABIGATRAN | VENOUS THROMBOEMBOLISM | WARFARIN | PERIPHERAL VASCULAR DISEASE | pulmonary embolism | HEMATOLOGY | STANDARD THERAPY | anticoagulant therapy | Recurrence | Pyrazoles - therapeutic use | Follow-Up Studies | Hemorrhage - epidemiology | Humans | Middle Aged | Male | Risk | Treatment Outcome | Enoxaparin - therapeutic use | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Hemorrhage - etiology | Venous Thromboembolism - complications | Adult | Female | Aged | Pyridones - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text An update of consensus guidelines for warfarin reversal
by Tran, Huyen A and Chunilal, Sanjeev D and Harper, Paul L and Tran, Huy and Wood, Erica M and Gallus, Alex S
Medical Journal of Australia, ISSN 0025-729X, 12/2014, Volume 201, Issue 11, pp. 645 - 645
Hematologic diseases | MEDICINE, GENERAL & INTERNAL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis
by Buller, Harry R and Destors, Jean-Michel and Gallus, Alex S and Pillion, Gerard and Prins, Martin H and Raskob, Gary E
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2011, Volume 9, Issue 1, pp. 92 - 99
treatment randomized trial | bioequipotency | auticoagulants | deep venous thrombosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights